Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up

• Published in: Maturitas 2007-06, Vol.57 (2), p.210-213
• Main Authors: Wildemeersch, D, Janssens, D, Pylyser, K, De Wever, N, Verbeeck, G, Dhont, M, Tjalma, W
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Endometrial hyperplasia; Endometrial Hyperplasia - drug therapy; Endometrial Hyperplasia - pathology; Estrogen Replacement Therapy; Female; Follow-Up Studies; Gynecology. Andrology. Obstetrics; Humans; Internal Medicine; Intrauterine Devices, Medicated; Intrauterine system (IUS); Levonorgestrel (LNG); Levonorgestrel - administration & dosage; Long-term study; Medical sciences; Middle Aged; Obstetrics and Gynecology; Progesterone Congeners - administration & dosage; Puberal and climacteric disorders (male and female); Treatment Outcome
• ISSN: 0378-5122; 1873-4111
• DOI: 10.1016/j.maturitas.2006.12.004

Abstract Objectives Levonorgestrel (LNG), delivered locally into the uterine cavity has a profound effect on the endometrium. The aim of the study was to use a LNG intrauterine system to treat non-atypical and atypical endometrial hyperplasia in women and to evaluate the long-term cure (remission) rate. Methods Each of the 20 women in the study, of whom eight were diagnosed with atypical hyperplasia, received a LNG–IUS, releasing 20 μg LNG/day. The study is a non-comparative study with long-term follow-up (range 14–90 months). Results All women developed a normal endometrium, except one asymptomatic woman with atypical hyperplasia who still had focal residual non-atypical hyperplasia at 3 years follow-up in the presence of a thin (